AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021
ACI-24 generated an encouraging immune response that correlated with a signal of target
engagement in patients with Down syndrome (DS)
Full Phase 1b results support the continued clinical development of anti-Abeta vaccine
approaches in DS-related Alzheimer’s disease (AD)
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today outlined two presentations being delivered at the Alzheimer’s Association International Conference (AAIC) 2021, taking place both in Denver, USA and virtually from July 26-30, 2021.